1. Neurological Disease

Neurological Disease

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1891
    β-Amyloid (22-40) 1206779-25-0 98%
    β-Amyloid (22-40) is a peptide fragment of β-Amyloid.
    β-Amyloid (22-40)
  • HY-P1893
    β-Amyloid (11-22) 885323-98-8 98%
    β-Amyloid (11-22) is a peptide fragment of β-Amyloid.
    β-Amyloid (11-22)
  • HY-P1894
    β-Amyloid Protein Precursor 770 (135-155) 315229-44-8 98%
    β-Amyloid Protein Precursor 770 (135-155) is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42.
    β-Amyloid Protein Precursor 770 (135-155)
  • HY-P1895
    β-Amyloid (33-40) 634204-57-2 98%
    β-Amyloid (33-40) is a peptide consisting of amino acid of 33 to 40 of beta amyloid protein.
    β-Amyloid (33-40)
  • HY-P1898
    β-Amyloid (13-27) 148270-13-7 98%
    β-Amyloid (13-27) is a peptide consisting of amino acid of 13 to 27 of beta amyloid protein.
    β-Amyloid (13-27)
  • HY-P1906
    [pThr3]-CDK5 Substrate 1670273-47-8 98%
    [pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM.
    [pThr3]-CDK5 Substrate
  • HY-P1962
    β-Secretase inhibitor 350228-37-4 98%
    β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC50: 25 nM for β-secretase).
    β-Secretase inhibitor
  • HY-P1987
    Mast cell degranulating peptide (28-49) 65636-54-6 98%
    Mast cell degranulating peptide (28-49) is a depolarizing agent from bee venom, it can raise the content of cGMP level in mouse cerebellar slices.
    Mast cell degranulating peptide (28-49)
  • HY-P1996
    Tiplimotide 178823-49-9 98%
    Tiplimotide (NBI-5788) is an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP). Tiplimotide can selectively reduce the production of inflammatory cytokines by pathogenic T-cells. Tiplimotide can be used for the research of multiple sclerosis (MS).
    Tiplimotide
  • HY-P2014
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin 114056-26-7 98%
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin is an oxytocin antagonist and can be used for the research of sexual behavior.
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin
  • HY-P2019
    Levitide 114281-19-5 98%
    Levitide is a neurohormone-like peptide, can be isolated from skin secretions of the South African frog Xenopus laevis. Levitide comes from preprolevitide, is 88 residues long and contains contains the levitide peptide at the C terminus (Glu-Gly-Met-Ile-Gly-Thr-Leu-Thr-Ser-Lys-Arg-Ile-Lys-Gln-NH2) and the putative signal sequence at the N terminus.
    Levitide
  • HY-P2042
    SALMF amide 1 134439-73-9 98%
    SALMF amide 1 is a neuropeptide.
    SALMF amide 1
  • HY-P2046
    β-Endorphin (rat) 309246-19-3 98%
    β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction.
    β-Endorphin (rat)
  • HY-P2083
    WWamide-2 149636-88-4 98%
    WWamide-2 is a neuropeptide, which can be isolated form Achatina fulica. WWamide-2 inhibits the rhythmic contraction of anterior byssus retractor muscle (ABRM).
    WWamide-2
  • HY-P2084
    WWamide-1 149665-72-5 98%
    WWamide-1 is a neuropeptide, which can be isolated form Achatina fulica. WWamide-1 inhibits central neurons of snails, regulates the snail muscle contraction. WWamide-1 inhibits the contraction of anterior byssus retractor muscle (ABRM), enhances the contraction of the radular traction muscle, through effects on presynaptic and postsynaptic membrane of the muscle.
    WWamide-1
  • HY-P2085
    WWamide-3 149636-89-5 98%
    WWamide-3 is a neuropeptide, which can be isolated form Achatina fulica. WWamide-3 inhibits the rhythmic contraction of anterior byssus retractor muscle (ABRM).
    WWamide-3
  • HY-P2113
    ORG-2766 50913-82-1 98%
    ORG-2766 is an adrenocorticotropic hormone ACTH 4-9 analog and neurotrophic peptide. ORG-2766 affects behavioral processes such as memory and attention in animals, improving symptoms in rats with experimental allergic neuritis. ORG-2766 has a neuroprotective effect.
    ORG-2766
  • HY-P2121
    JMV 176 119068-32-5 98%
    Jmv 176 is a CCK agonist when first given and becomes a cholecystokinin antagonist after 3-4 hours.
    JMV 176
  • HY-P2150
    Cortistatin-29 (rat) 1815618-17-7 98%
    Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects.
    Cortistatin-29 (rat)
  • HY-P2165
    N-acetyl CCK-(26-30) amide 89911-69-3 98%
    N-acetyl CCK-(26-30) amide (CCK-(26-30) (sulfated)) is a cholecystokinin (CCK) receptor antagonist.
    N-acetyl CCK-(26-30) amide
Cat. No. Product Name / Synonyms Application Reactivity